Biogen Pledges $2 Billion Manufacturing Investment in North Carolina

Biogen announced a $2 billion investment over the next three years to expand and upgrade factories at its two large manufacturing campuses in North Carolina's Research Triangle Park (RTP)245.

This brings Biogen's total investment in North Carolina drug manufacturing to $10 billion since 1995, including $3 billion in recent years1.

The new investment will expand Biogen's antisense oligonucleotide capabilities and infrastructure, establish clinical and commercial scale multi-platform fill-finish operations, and further modernize manufacturing technologies with automation and artificial intelligence13.

Biogen employs roughly 1,500 manufacturing and technical workers across its RTP campuses1.

A new 197,000-square-foot facility, initially designed for gene therapy production and clinical packaging, is nearing completion; its future use is being reviewed as Biogen shifts investment priorities1.

Biogen produces leading drugs like Avonex, Plegridy, Tysabri, and Qalsody at existing RTP facilities, with Spinraza joining the production list this year1.

The company highlighted its commitment as part of its 30th anniversary in North Carolina4.

Sources:

1. https://www.biospace.com/business/biogen-commits-2b-to-expand-us-drug-production-amid-tariff-talk

2. https://www.fiercepharma.com/manufacturing/biogen-ups-its-ante-north-carolina-pledging-2b-manufacturing-investment

3. https://www.bizjournals.com/triangle/news/2025/07/21/biogen-rtp-expansion-manufacturing-biotech.html

4. https://investors.biogen.com/news-releases/news-release-details/biogen-announces-2-billion-manufacturing-investment-north

5. https://www.axios.com/local/raleigh/2025/07/21/biogen-investment-research-triangle-park-manufacturing-facilities-north-carolina